CTRI/2019/05/019367尚未招募2 期
Early integrated palliative care versus routine oncological care for advanced adultsarcoma patients in tertiary care center in India: a randomised phase II trial
VIKAS GARG0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Subjects with histologically confirmed diagnosis of advanced sarcoma not being treated with curative intent.
- •2.Diagnosed within the previous 8 weeks.
- •3.No prior therapy for metastatic disease.
- •4.Subjects who are willing to provide written informed consent.
- •5.Ability to understand questions in Hindi or English.
- •6.Male or female subjects, 18 years of age and older.
排除标准
- •1.Subjects who are already receiving palliative care.
- •2.Subjects requiring immediate referral to hospice.
- •3.Subjects with any communication disability, history of or current neurological or psychiatric impairment, or cognitive dysfunction, active brain metastases.
研究者
相似试验
已完成
1 期
Early specialty palliative care for patients with advanced lung cancer undergoing chemotherapy: Feasbility studyAdvanced Lung CancerJPRN-UMIN000012772ational Cancer Center Hospital East50
已完成
不适用
Early Palliative Care for patients with symptomatic Heart FailureI50.12I50.13I50.14DRKS00013922niklinik BonnMedizinische Klinik II206
招募中
不适用
The effect of early palliative care on quality of life and self-care behaviours in patient with type2 diabetesDiabetes mellitusIRCT20231107059976N1Tehran University of Medical Sciences100
已完成
不适用
A randomised phase 3 trial of Palliative care Early in Advanced Lung Cancers.Adults with advanced thoracic malignancy (NSCLC, SCLC orMPM) that have been newly diagnosed within the last 60 days.Adults with advanced thoracic malignancy (NSCLC, SCLC orMPM) that have been newly diagnosed within the last 60 days.Cancer - Lung - Small cellCancer - Lung - Non small cellCancer - Lung - MesotheliomaACTRN12617000166370niversity of Sydney113
进行中（未招募）
不适用
Palliative care with or without palliative chemotherapy: clinical trial.Patients with advanced cancer.EUCTR2012-001128-36-ESInstitut de Recerca HSCSP